EFB Dengue Literature Review

Toll-like Receptor Signaling in B Cells

13 min read

Toll-like Receptor Signaling in B Cells

Overview

Endosomal Toll-like receptors — principally TLR7 (single-stranded RNA) and TLR9 (unmethylated CpG DNA) — are the innate arm of the signal set that builds DN2 / atypical B cells. This page covers the wiring: what the receptors do downstream, what restrains them, how they combine with cytokine and BCR input, and when in the differentiation sequence they act.

Marker-level detail lives on TLR7 and TLR9; this page routes rather than duplicates. The complementary signals are covered on IFN-gamma, IL-21 and B Cell Receptor Signaling.

Background context (not sourced to an ingested paper): TLR7 and TLR9 are endosomal, signal through MyD88, and converge on NF-κB and MAPK cascades. The wiki has no ingested source describing MyD88 itself, so no MyD88 page exists.

Key Points from Literature

The signal is hyper-responsive in DN2 cells, and the brake is missing

TLR7 rewires the cell’s inhibitory and antigen-presenting surface

  • TLR7 stimulation upregulates HLA-DR and CD86 while downregulating the inhibitory receptors CD72 and CD32b (FcγRIIB) on DN2 cells (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, human phospho-flow n=5–10)
  • This is the wiki’s only primary evidence assigning a direction to CD72 and CD32b regulation, and it sets up an unresolved paradox — see Contradictions.

Timing: TLR7/8 acts at both ends of the differentiation sequence

  • In the reconstructed human differentiation system, R848 is important throughout, but with two distinct jobs: early TLR7/8 supports B cell survival; late TLR7/8 drives proliferation (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human in vitro, ≥3 experiments)
  • R848 given only during days 0–3 produced no ASCs (proliferation severely stunted); R848 given only during days 3–6 left pre-ASC formation and ASC frequency intact but reduced total cell recovery (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation)
  • ⚠ Corrected 2026-08-23. Omitting R848 from the day-3 cocktail did not impair T-bet⁺IRF4⁺ induction — the paper reports results “similar” to the all-signal condition when R848 (or anti-Ig, IL-21, BAFF or IL-2) was left out; only IFN-γ omission broke pre-ASC induction. What R848 omission does cost is the endpoint: ASC recovery across the full 6 days falls to background without it. This bullet previously read “dropped T-bet⁺IRF4⁺ induction from ~8% to ~13% of the all-signal condition”; neither number appears in the paper’s text and the direction was wrong (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, Figure 4f–l, re-verified against the PDF)

TLR7 does not act alone — the IFN-γ synergy is the key interaction

TLR9 is the tolerance-side receptor

  • CpG drives DN B cell proliferation without BCR crosslinking, and upregulates CD27 — establishing both that TLR9 alone is a sufficient mitogen for these cells and that the CD27⁻ phenotype is plastic (see Wei2007 - DN Memory B Cells in SLE, human)
  • TLR9 is described as a tolerance checkpoint, with the striking implication that molecular pattern recognition of internalised antigen components, rather than BCR epitope specificity per se, underlies peripheral B cell tolerance (see Cancro2020 - Age-Associated B Cells, review, murine — attributed to un-ingested work)
  • Pathway analysis of the DN2 transcriptional network predicted TLR7 and TLR9 as upstream regulators even though no TLR ligands were added to the cultures, attributed to endogenous ligands released by dying cells (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human)

In dengue specifically

  • The TLR7/8 ligand R-848 reproduced DENV’s conversion of monocytes to the plasmablast-driving CD14⁺CD16⁺ phenotype, whereas the TLR4 ligand LPS did not (see Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue, human in vitro, 4 donors) — implicating endosomal ssRNA sensing rather than surface TLR signalling in the dengue innate response

  • Toll-like receptor signalling was among the top pathways associated with high viral load in acute dengue whole blood (see Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue, n=28 acute)

  • Note this is TLR signalling in monocytes, not B cells. No ingested source has measured B cell TLR responsiveness in dengue.

  • ★ Dengue virus itself engages human TLR7 — first primary demonstration in the wiki. IFN-α induced from human Plasmacytoid Dendritic Cells by live dengue-2 virus was significantly reduced by the TLR7 antagonist IRS 661 (p < 0.02), and transmission EM placed enveloped D2V particles inside endocytic vacuoles within 5 min of warming to 37 °C (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling, in vitro, n=4 independent experiments, pDCs >85% pure). This is a step beyond the Kwissa2014 result above: there an agonist mimicked DENV’s effect; here the virus is blocked at the receptor.

  • ⚠ Restating the gap precisely. The line above remains true as written — no ingested source has measured B cell TLR responsiveness in dengue. What has changed is that two ingested sources now measure a non-B-cell response to dengue through the endosomal ssRNA sensor: monocytes (Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue) and pDCs (Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling). The sensing machinery is demonstrably engaged in dengue, in the right compartment, by the right ligand — in two myeloid/dendritic cell types, and nobody has looked at the B cell.

  • TLR7 has two output arms with different activation thresholds, and which one a cell can run is a property of the cell. In a TLR Reporter Cell Assay, ligands formed a stepwise series: short synthetic RNAs (nothing) → R-848 and poly(U) (NF-κB/IL-8 only) → genomic viral RNAs (both arms). But primary pDCs made 13,694–18,381 pg/ml IFN-α to the same R-848 that gave none in the reporter line, which the authors attribute to pDCs’ higher levels of limiting downstream components (IRF-7 named) (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling, in vitro). Consequence for this wiki: a negative in a reporter line is not a negative for the ligand, and B cells’ position on this axis is unmeasured. See TLR7 Contradictions & Debates.

  • Ligand potency at TLR7 is set by higher-order RNA structure — genomic viral RNA is 50–1000× more potent than the short synthetic ssRNAs used as standard reagents. Potency was not strictly length-dependent, UV cross-linking (which alters tertiary structure) cut dengue-2 vRNA signalling to 23–40% while barely touching influenza vRNA, and removing 5′-phosphates had no effect at all (see Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling, in vitro). This matters for transferring the SLE-derived model into dengue — see the potency-class argument under TLR7 Contradictions & Debates.

  • ★ Germline variation in the TLR genes does not stratify dengue clinical form — except at TLR4, and not by severity. Genotyping 13 SNPs across TLR3, TLR4, TLR7 and TLR8 in 165 adult dengue patients and 89 controls, the crude analysis was null for TLR3, TLR7 and TLR8. Two TLR4 promoter variants were associated with protection from dengue relative to controls (rs2737190-G/G, OR 0.34, 95% CI 0.14–0.8, p=0.038; rs11536865-G/C, OR 0.19, 95% CI 0.05–0.73, p=0.0092), as was a TGCG haplotype (OR 0.55, 95% CI 0.35–0.86, p=0.0084) — but no haplotype or genotype separated DF from DHF (see Posadas-Mondragon2020 - TLR Polymorphisms and Clinical Forms of Dengue, n=254 case-control, WHO 1997, DENV-2-dominant). The TLR4 signal is also the extracellular, NS1-facing arm of TLR biology (dengue NS1 hexamer activates macrophages and PBMCs via TLR4, per Modhiran 2015 cited therein), not the endosomal ssRNA arm this page is about.

  • A null association study does not test whether the pathway is used. Germline genotyping asks whether inherited variation stratifies outcome; every other bullet on this page concerns whether signalling occurs. An essential pathway is expected to lack common functional variation. The reasoning is set out in full under Contradictions & Debates on TLR7; it is recorded here so the dengue section is not read as evidence against the endosomal-TLR mechanism.

  • The one thing that study adds methodologically: TLR7 and TLR8 are X-linked, so it analysed them separately by sex — the first infection cohort in this wiki forced to do so. Its DHF-women stratum was n=28, which is why nothing interpretable came out (see SNP Genotyping).

  • ★ TLR9 and TLR7 bias the response differently — the consensus synthesis (Box 2) separates them. Antigens that strongly crosslink TLR9 together with the BCR potently drive EF responses; particulate foreign antigens conjugated to CpG predominantly elicit EF responses. By contrast, antigens containing TLR7 ligands induce both robust GC and EF antibody responses. The wiki’s working model has treated endosomal ssRNA sensing as the EF-biasing input; on this reading TLR7 amplifies both arms in a type-1 direction rather than switching between them (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • A TLR route to ASC commitment that bypasses the IL-21/STAT3 axis. Strong BCR and/or TLR signalling drives NF-κB c-Rel-mediated induction of IRF4, the master regulator of ASC development. B cell-intrinsic MyD88 and TRIF were both required for strong extrafollicular plasmablast development after influenza A infection, acting through enhanced c-Rel nuclear translocation. The authors note this may link EF plasmablast responses to high-affinity antigens and TLR engagement jointly (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • Cytokines gate what TLR signalling can do. IL-4 suppresses the ability of TLR7 to drive EF responses, and IL-4/IL-13 support migration into the follicle to form GCs; IL-12 and IFN-γ favour EF responses. TLR7 in combination with IFN-γ acts cell-autonomously in mouse B cells to raise T-bet, which facilitates IgG2a/IgG2c class switching (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • TLR7/9 are required for GC-independent autoantibody production. Anti-nuclear antibodies still require TLR7 and/or TLR9 in mice that lack GCs — evidence that the EF arm alone is sufficient for pathogenic autoantibody output. The authors add a framing the wiki should carry into the dengue context: the relevant TLR7 ligands may be self nucleic acids or foreign ssRNA from viruses such as SARS-CoV-2, so the co-presence and concentration of TLR ligands with antigen determines this response type, “rather than whether the target antigen is of self or foreign origin” (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data). See GC-Independent Response and TLR7.

  • ★ Sustained TLR signalling is sufficient to block terminal differentiation — a causal, not correlative, result. Adding TLR7 (R848) or TLR9 (CpG) ligands to wild-type mouse Be1 cultures from day 2 significantly reduced CD138⁺CD93⁺ ASC and IgG-secreting cell numbers, phenocopying T-bet deletion; an NF-κB activator (betulinic acid) did the same. Proliferation was unaffected, excluding a growth artefact (see Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation, mouse, in vitro). Tbx21^−/−^ Be1 cells correspondingly maintained high expression of NF-κB family members and increased TLR and TNFR family receptors and ligands that wild-type cells extinguish by day 4. The implication for this page is that TLR signalling in B cells has opposite effects at different stages — activating and differentiating early, differentiation-blocking when sustained — and that a B cell unable to downmodulate its TLR/NF-κB network is impaired at becoming an ASC.

Contradictions & Debates

★ The inhibitory-receptor paradox. DN2 cells are reported as CD32b^hi^ and CD22^hi^ in their steady-state phenotype (see Jenks2018 - DN2 B Cells and EF Pathway in SLE) — high for two ITIM-bearing inhibitory receptors — yet are simultaneously hyper-responsive to TLR7. Part of the resolution may be that TLR7 stimulation itself downregulates CD72 and CD32b, so the inhibitory phenotype is the pre-stimulation state and is dismantled on activation. The wiki has no data on ITIM phosphorylation or phosphatase recruitment in these cells and cannot resolve this. Recorded as open.

Same input, opposite fate. Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation’s discussion cites work (Jackson et al. 2016, not ingested) in which IFN-γ synergising with TLR7 and CD40 promotes Bcl6 upregulation and a germinal-centre-like phenotype — the opposite outcome to the EF/ASC fate produced by IFN-γ + TLR7 without CD40. This fits Jenks2018 - DN2 B Cells and EF Pathway in SLE’s finding that CD40L inhibits EF differentiation, suggesting CD40 engagement is the switch. Held as a hypothesis; the wiki has no ingested primary testing it directly.

TLR7, TLR9, TRAF5, IFN-gamma, IL-21, B Cell Receptor Signaling, DN2 B Cell, Extrafollicular Response, Atypical B Cell Effector Output, In Vitro B Cell Stimulation, Phospho-Flow Cytometry, SNP Genotyping, Dengue Severity Classification, Plasmacytoid Dendritic Cell, Type I Interferon, TLR Reporter Cell Assay, GC-Independent Response

Sources

Graph View

Backlinks